224 related articles for article (PubMed ID: 38410245)
1. Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach.
Murtagh G; deFilippi C; Zhao Q; Barac A
Front Cardiovasc Med; 2024; 11():1350585. PubMed ID: 38410245
[TBL] [Abstract][Full Text] [Related]
2. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
Lehmann LH; Heckmann MB; Bailly G; Finke D; Procureur A; Power JR; Stein F; Bretagne M; Ederhy S; Fenioux C; Hamwy O; Funck-Brentano E; Romano E; Pieroni L; Münster JP; Allenbach Y; Anquetil C; Leonard-Louis S; Palaskas NL; Hayek SS; Katus HA; Giannitsis E; Frey N; Kaya Z; Moslehi J; Prifti E; Salem JE
Circulation; 2023 Aug; 148(6):473-486. PubMed ID: 37317858
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge.
Frascaro F; Bianchi N; Sanguettoli F; Marchini F; Meossi S; Zanarelli L; Tonet E; Serenelli M; Guardigli G; Campo G; Calabrò L; Pavasini R
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137806
[TBL] [Abstract][Full Text] [Related]
4. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review.
Gul R; Shehryar M; Mahboob A; Kareem HK; Inayat A; Safi D; Kamran A
Cureus; 2024 Jan; 16(1):e52952. PubMed ID: 38406102
[TBL] [Abstract][Full Text] [Related]
7. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications.
Wong CK; Lam TH; Liao SY; Lau YM; Tse HF; So BYF
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672615
[TBL] [Abstract][Full Text] [Related]
8. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
9. Successful Therapy for Myocarditis Concomitant With Complete Heart Block After Pembrolizumab Treatment for Head and Neck Squamous Cell Carcinoma: A Case Report With Literature Review.
Su L; Liu C; Wu W; Cui Y; Wu M; Chen H
Front Cardiovasc Med; 2022; 9():898756. PubMed ID: 35647073
[TBL] [Abstract][Full Text] [Related]
10. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors.
Reyes-Gibby CC; Qdaisat A; Ferrarotto R; Fadol A; Bischof JJ; Coyne CJ; Lipe DN; Hanna EY; Shete S; Abe JI; Yeung SJ
Head Neck; 2024 Mar; 46(3):627-635. PubMed ID: 38151809
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.
Zito C; Manganaro R; Ciappina G; Spagnolo CC; Racanelli V; Santarpia M; Silvestris N; Carerj S
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358830
[TBL] [Abstract][Full Text] [Related]
13. Cardiac imaging techniques for the assessment of immune checkpoint inhibitor-induced cardiotoxicity and their potential clinical applications.
Li Y; Liu PJ; Zhang ZL; Wang YN
Am J Cancer Res; 2022; 12(8):3548-3560. PubMed ID: 36119829
[TBL] [Abstract][Full Text] [Related]
14. How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy.
Spallarossa P; Sarocchi M; Tini G; Arboscello E; Toma M; Ameri P; Porto I
Front Pharmacol; 2020; 11():972. PubMed ID: 32676031
[TBL] [Abstract][Full Text] [Related]
15.
Boughdad S; Latifyan S; Fenwick C; Bouchaab H; Suffiotti M; Moslehi JJ; Salem JE; Schaefer N; Nicod-Lalonde M; Costes J; Perreau M; Michielin O; Peters S; Prior JO; Obeid M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34686542
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
[TBL] [Abstract][Full Text] [Related]
17. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.
Cau R; Solinas C; De Silva P; Lambertini M; Agostinetto E; Scartozzi M; Montisci R; Pontone G; Porcu M; Saba L
Int J Cancer; 2022 Dec; 151(11):1860-1873. PubMed ID: 35730658
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience.
Xiao J; Li X; Wang X; Guan Y; Liu H; Liang J; Li Y; Wang B; Wang J
Front Cardiovasc Med; 2023; 10():1093383. PubMed ID: 37089888
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis.
Dolladille C; Akroun J; Morice PM; Dompmartin A; Ezine E; Sassier M; Da-Silva A; Plane AF; Legallois D; L'Orphelin JM; Alexandre J
Eur Heart J; 2021 Dec; 42(48):4964-4977. PubMed ID: 34529770
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]